Avidity Biosciences, Inc. (RNA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Avidity Biosciences, Inc. (RNA) trades at $13.48 with AI Score 31/100 (Grade D). Atrium Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA therapeutics for cardiomyopathies. Market cap: $231M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 9, 2026RNA stock analysis for 2026: Analysts have set a consensus price target of $25.00 for Avidity Biosciences, Inc., suggesting 85.5% upside from the current price of $13.48. The AI MoonshotScore is 31/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
RNA: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Avidity Biosciences, Inc. (RNA) Healthcare & Pipeline Overview
Atrium Therapeutics, Inc. is a biopharmaceutical company specializing in RNA therapeutics for cardiomyopathies, including ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy. Incorporated in 2025, the company operates from its San Diego headquarters, focusing on innovative treatments for genetic and cardiac diseases.
What Is the Investment Thesis for RNA?
Atrium Therapeutics presents a focused investment opportunity within the biotechnology sector, specifically targeting RNA-based therapies for cardiac diseases. The company's lead candidates, ATR 1072 and ATR 1086, address specific genetic cardiomyopathies with significant unmet medical needs. A key value driver is the potential for these therapies to achieve clinical success and regulatory approval, leading to substantial market penetration. Growth catalysts include the advancement of these candidates through clinical trials and expansion of the pipeline. The company's high gross margin of 100.0% indicates strong potential profitability upon commercialization. However, the company's negative profit margin of -411.9% reflects its current R&D-heavy stage. Investment risks include clinical trial failures, regulatory hurdles, and competition from other companies developing cardiac therapies.
Based on FMP financials and quantitative analysis
RNA Key Highlights
Market capitalization of $231M, reflecting investor valuation of Atrium Therapeutics' pipeline and potential.
- Gross margin of 100.0% indicates strong potential profitability upon commercialization of its RNA therapeutics.
- Negative profit margin of -411.9% due to significant R&D investment in developing novel therapies.
- Focus on siRNA-based therapies targeting PRKAG2 and PLN, addressing specific genetic cardiomyopathies.
- Pipeline expansion targeting a range of genetic and cardiac diseases, demonstrating commitment to innovation in cardiology.
Who Are RNA's Competitors?
RNA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.21% | $196M | 77 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| MDXG MiMedx Group, Inc. | $4.45 | +2.53% | $649M | 90 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RNA's Key Strengths?
Focus on innovative RNA therapeutics.
- Pipeline of siRNA-based therapies.
- Strong intellectual property position.
- Experienced management team.
What Are RNA's Weaknesses?
Limited commercialized products.
- Dependence on clinical trial success.
- High R&D expenses.
- Negative profit margin.
What Could Drive RNA Stock Higher?
Clinical trial results for ATR 1072 in PRKAG2 syndrome.
- Clinical trial results for ATR 1086 in PLN cardiomyopathy.
- Expansion of the therapeutic pipeline to address additional cardiac diseases.
- Strategic partnerships and collaborations with larger pharmaceutical companies.
- Regulatory submissions for ATR 1072 and ATR 1086.
What Are the Key Risks for RNA?
Negative return on equity (-29.7%) — the business is not currently generating profit on shareholder capital.
- Clinical trial failures for ATR 1072 and ATR 1086.
- Regulatory hurdles and delays in approval process.
- Competition from other companies developing cardiac therapies.
- Changes in healthcare regulations affecting drug pricing and reimbursement.
- High R&D expenses and potential need for additional funding.
What Are the Growth Opportunities for RNA?
- Expansion of the therapeutic pipeline: Atrium Therapeutics has the opportunity to broaden its pipeline beyond ATR 1072 and ATR 1086 to address a wider range of genetic and cardiac diseases. This involves identifying new therapeutic targets and developing novel RNA-based therapies. The market for cardiac disease treatments is substantial, with a global market size estimated at hundreds of billions of dollars. Successful pipeline expansion could significantly increase Atrium's market share and revenue potential. Timeline: Ongoing.
- Advancement of ATR 1072 for PRKAG2 syndrome: ATR 1072, a siRNA-based therapy targeting PRKAG2, represents a significant growth opportunity for Atrium Therapeutics. PRKAG2 syndrome is a rare genetic cardiomyopathy with limited treatment options. Successful clinical development and regulatory approval of ATR 1072 could establish Atrium as a leader in this niche market. The orphan drug designation could provide market exclusivity and pricing advantages. Timeline: Ongoing clinical trials.
- Development of ATR 1086 for PLN cardiomyopathy: ATR 1086, a siRNA-based therapy targeting PLN, is another key growth driver for Atrium Therapeutics. PLN cardiomyopathy is a severe inherited heart condition with a high mortality rate. Effective treatment options are lacking, creating a significant unmet medical need. Positive clinical trial results and regulatory approval of ATR 1086 could generate substantial revenue and improve patient outcomes. Timeline: Ongoing clinical trials.
- Strategic partnerships and collaborations: Atrium Therapeutics can pursue strategic partnerships and collaborations with larger pharmaceutical companies or academic institutions to accelerate the development and commercialization of its RNA therapeutics. These partnerships could provide access to additional funding, expertise, and resources. Collaborations could also expand Atrium's reach into new markets and therapeutic areas. Timeline: Ongoing.
- Geographic expansion: Atrium Therapeutics has the potential to expand its geographic reach beyond the United States to address the global market for cardiac disease treatments. This could involve establishing operations in Europe, Asia, and other regions. Geographic expansion would require significant investment in infrastructure and regulatory compliance. However, it could also unlock new revenue streams and increase Atrium's overall market share. Timeline: 3-5 years.
What Are RNA's Competitive Advantages?
- Proprietary siRNA-based therapy platform.
- Focus on specific genetic cardiomyopathies with unmet medical needs.
- Strong intellectual property protection for its product candidates.
- Expertise in RNA therapeutics and cardiac disease biology.
What Does RNA Do?
Atrium Therapeutics, Inc., established in 2025, is a biopharmaceutical company dedicated to pioneering ribonucleic acid (RNA) therapeutics for the treatment of cardiomyopathies. Headquartered in San Diego, California, the company focuses on developing innovative therapies that target the underlying genetic causes of heart diseases. Atrium's lead product candidates include ATR 1072, a siRNA-based therapy designed to treat PRKAG2 syndrome, and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. These therapies represent a novel approach to addressing inherited heart conditions by directly modulating gene expression. Beyond these lead candidates, Atrium Therapeutics is actively expanding its pipeline to address a range of genetic and cardiac diseases. The company's research and development efforts are centered on leveraging the potential of RNA therapeutics to deliver targeted and effective treatments for patients with unmet medical needs in the field of cardiology. With a team of 511 employees, Atrium Therapeutics is committed to advancing the science of RNA therapeutics and transforming the care for individuals affected by cardiomyopathies.
What Products and Services Does RNA Offer?
- Develop RNA therapeutics for the treatment of cardiomyopathies.
- Focus on siRNA-based therapies targeting genetic heart diseases.
- Develop ATR 1072, a siRNA-based therapy for PRKAG2 syndrome.
- Develop ATR 1086, a siRNA-based therapy for PLN cardiomyopathy.
- Expand pipeline to treat a range of genetic and cardiac diseases.
- Conduct research and development to advance RNA therapeutics.
- Seek regulatory approval for its product candidates.
How Does RNA Make Money?
- Develop and commercialize RNA therapeutics for cardiac diseases.
- Generate revenue through sales of approved therapies.
- Out-license or partner with other companies for development and commercialization.
- Focus on proprietary siRNA-based therapies.
What Industry Does RNA Operate In?
Atrium Therapeutics operates within the rapidly evolving biotechnology industry, specifically focusing on RNA therapeutics for cardiac diseases. The market for RNA-based therapies is experiencing significant growth, driven by advancements in drug delivery technologies and a deeper understanding of gene regulation. The competitive landscape includes both established pharmaceutical companies and smaller biotech firms also developing RNA therapeutics. Atrium Therapeutics aims to differentiate itself through its focus on specific genetic cardiomyopathies and its innovative siRNA-based therapies. The company's success will depend on its ability to navigate the complex regulatory environment and demonstrate clinical efficacy in its target patient populations.
Who Are RNA's Key Customers?
- Patients with PRKAG2 syndrome.
- Patients with PLN cardiomyopathy.
- Hospitals and clinics specializing in cardiology.
- Healthcare providers treating genetic heart diseases.
Avidity Biosciences, Inc. Financial Trajectory
Avidity Biosciences, Inc. (RNA) reported $3.0M in revenue for Q2 2026, a decline of 84.7% compared to the prior quarter. The company recorded a net loss of $20.2M, with diluted EPS of $-1.18. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare.
Company Profile
Avidity Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Kathleen Gallagher. RNA has traded publicly since 2026.
How Avidity Biosciences, Inc. Is Valued
Avidity Biosciences, Inc. carries a market capitalization of $231M, placing it in the micro-cap category. Relative to its peer group, RNA's quantitative score of 31/100 is below the peer average of 74/100.
Key Financial Metrics
Return on equity for Avidity Biosciences, Inc. stands at -29.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -22.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -23.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 13.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -28.4%, the inverse of the P/E and a quick read on earnings relative to price.
Earnings Track Record
Avidity Biosciences, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 12.4% above estimates on average.
Forward Outlook
Wall Street analysts project Avidity Biosciences, Inc. revenue of about $21.6M for fiscal 2026, with EPS near $-4.70. The estimate reflects 3 contributing analysts.
RNA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Avidity's future prospects, indicating that key stakeholders believe in the company's potential.
- Community sentiment has shifted positively, with discussions highlighting the innovative nature of Avidity's RNA-targeted therapies.
- Positive developments in clinical trials have been shared within trading circles, bolstering belief in the company's ability to deliver breakthroughs.
- Analysts are increasingly optimistic about the long-term impact of Avidity's technology on treating various diseases, which resonates with investor sentiment.
Bear Case
- Concerns about the competitive landscape have emerged, with some traders noting that rival companies are advancing their own RNA therapies.
- Recent social sentiment reflects skepticism regarding the timeline for Avidity's product launches, leading to doubts about short-term performance.
- Some community members are cautious about the company's financial health, questioning its ability to fund ongoing research and operations without additional capital.
- Market perception has been tempered by broader economic uncertainties, causing some investors to adopt a more cautious stance on biotech stocks like Avidity.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $3M | -$20M | -$1.18 |
| Q1 2026 | $20M | -$17M | -$0.97 |
| Q4 2025 | $859,000 | -$48M | -$1.70 |
Based on FMP financials and quantitative analysis
RNA Latest News
No recent news available for RNA.
RNA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RNA.
Price Targets
Consensus target: $25.00
RNA MoonshotScore
What does this score mean?
The MoonshotScore rates RNA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest Avidity Biosciences, Inc. Analysis
Leadership: Kathleen Gallagher
CEO
Kathleen Gallagher serves as the CEO of Atrium Therapeutics, leading the company's efforts in developing RNA therapeutics for cardiomyopathies. Her career spans various leadership roles within the biotechnology and pharmaceutical industries. Prior to Atrium, she held executive positions at multiple companies, focusing on strategic development and commercialization of novel therapies. Gallagher holds an advanced degree in molecular biology and an MBA from a leading business school.
Track Record: Under Kathleen Gallagher's leadership, Atrium Therapeutics has advanced its lead product candidates, ATR 1072 and ATR 1086, through preclinical and early clinical development. She has overseen the expansion of the company's pipeline and secured strategic partnerships to support its growth. Her strategic decisions have focused on building a strong intellectual property portfolio and attracting top talent to the organization.
Avidity Biosciences, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for RNA?
RNA holds an AI Score of 31/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. Atrium Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA therapeutics for cardiomyopathies. Their pipeline includes siRNA-based therapies targeting genetic and cardiac …
What does Atrium Therapeutics, Inc. do?
Atrium Therapeutics, Inc. is a biopharmaceutical company focused on developing and delivering ribonucleic acid (RNA) therapeutics to the heart, aiming to transform the care for people living with cardiomyopathies. Their primary focus is on creating innovative treatments for genetic and cardiac diseases through targeted RNA modulation.
What do analysts say about RNA stock?
Analyst coverage of Atrium Therapeutics (RNA) is currently limited, reflecting the company's relatively recent incorporation in 2025 and its focus on early-stage clinical development. Key valuation metrics are still evolving as the company progresses its lead candidates, ATR 1072 and ATR 1086, through clinical trials.
What are the main risks for RNA?
Atrium Therapeutics faces several key risks inherent to the biotechnology industry. Clinical trial risk is significant, as the success of ATR 1072 and ATR 1086 depends on demonstrating safety and efficacy in human trials. Regulatory risk is also present, as the company must navigate complex FDA approval processes. Competition from other companies developing cardiac therapies poses a threat.
What are the key factors to evaluate for RNA?
Avidity Biosciences, Inc. (RNA) holds an AI score of 31/100 (low). Analysts target $25.00 (+85%). Atrium Therapeutics presents a focused investment opportunity within the biotechnology sector, specifically targeting RNA-based therapies for cardiac diseases. Not financial advice.
How frequently does RNA data refresh on this page?
RNA's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RNA's recent stock price performance?
Avidity Biosciences, Inc. (RNA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on innovative RNA therapeutics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RNA overvalued or undervalued right now?
Avidity Biosciences, Inc. (RNA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $25.00 (+85%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RNA before investing?
Before investing in Avidity Biosciences, Inc. (RNA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Analyst opinions may vary.